Chantal Parpex
Directeur/Membre du Conseil chez Kayentis SAS
Profil
Chantal Parpex is a Senior Managing Director at LBO France Gestion SAS and a Director at Kayentis SAS.
She was previously a Director at IntegraGen SA, Cytheris SA, INSERM Transfert SA, and Bioring SA. She was also the Managing Director at Rhone DPC Europe and the Director-Laboratory Development at Rhone Poulanc Rorer, Inc. Chantal was the President & Managing Partner at Innovation Capital SASU and a Member-Supervisory Board at Novagali Pharma SA. Dr. Parpex received her undergraduate degree from INSEAD and her doctorate from Université de Paris 5 René Descartes.
Postes actifs de Chantal Parpex
| Sociétés | Poste | Début |
|---|---|---|
Kayentis SAS
 Kayentis SAS Packaged SoftwareTechnology Services Kayentis SAS provides software in clinical trials solutions. It publishes and operates digital pen and smart paper solutions for the healthcare industry. The firm provides eCOA and eCRF solutions for trial management. It operates through its offices located in Gif-sur-Yvette and Saint Louis. The company was founded by Philippe Berna in 2009 and is headquartered in Gif-sur-Yvette, France. | Directeur/Membre du Conseil | - |
LBO France Gestion SAS
 LBO France Gestion SAS Investment ManagersFinance LBO France Gestion SAS (LBO France) is one of the oldest independent private equity firms in France. Established in 1985, the firm manages leveraged buyout transactions through their small-cap, mid-cap and real estate funds. Headquartered in Paris, LBO France primarily targets French firms or companies which are based or which transact most of their business in France. | Private Equity Investor | 18/11/2016 |
Anciens postes connus de Chantal Parpex
| Sociétés | Poste | Fin |
|---|---|---|
Innovation Capital SASU
 Innovation Capital SASU Investment ManagersFinance Innovation Capital SASU (Innovation Capital) is the international venture capital subsidiary of CDC Capital Investissement SAS, itself a wholly-owned subsidiary of State-owned CDC Caisse des Dépôts et Consignations in France. Established in 1996 as CDC Entreprises Innovation, the firm was formerly known as CDC Innovation SASU. They changed their name to Innovation Capital SASU in 2012. Located in Paris with representative offices in California and in Switzerland, the firm manages venture capital and innovation mutual funds (FCPRs and FCPIs). Their venture capital funds are sponsored by CDC Capital Investissement, and the innovation funds are generally co-invested with the venture capital funds. The firm's mandate includes public interest missions. | President | 18/11/2016 |
| INTEGRAGEN | Directeur/Membre du Conseil | 12/01/2015 |
Bioring SA
 Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | Directeur/Membre du Conseil | 05/04/2013 |
Novagali Pharma SA
 Novagali Pharma SA Pharmaceuticals: MajorHealth Technology Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France. | Directeur/Membre du Conseil | 11/10/2011 |
| Rhone Poulanc Rorer, Inc. | Corporate Officer/Principal | 01/01/1997 |
Formation de Chantal Parpex
| INSEAD | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INTEGRAGEN | Health Services |
| Entreprise privées | 10 |
|---|---|
Innovation Capital SASU
Innovation Capital SASU Investment ManagersFinance Innovation Capital SASU (Innovation Capital) is the international venture capital subsidiary of CDC Capital Investissement SAS, itself a wholly-owned subsidiary of State-owned CDC Caisse des Dépôts et Consignations in France. Established in 1996 as CDC Entreprises Innovation, the firm was formerly known as CDC Innovation SASU. They changed their name to Innovation Capital SASU in 2012. Located in Paris with representative offices in California and in Switzerland, the firm manages venture capital and innovation mutual funds (FCPRs and FCPIs). Their venture capital funds are sponsored by CDC Capital Investissement, and the innovation funds are generally co-invested with the venture capital funds. The firm's mandate includes public interest missions. | Finance |
Bioring SA
Bioring SA Medical SpecialtiesHealth Technology Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development | Health Technology |
Cytheris SA
 Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Health Technology |
Novagali Pharma SA
Novagali Pharma SA Pharmaceuticals: MajorHealth Technology Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France. | Health Technology |
| Rhone Poulanc Rorer, Inc. | |
| Rhone DPC Europe | |
INSERM Transfert SA
 INSERM Transfert SA Investment ManagersFinance INSERM Transfert SA is a Venture Capital firm, a subsidiary of Institut National de la Sant? et de la Recherche M?dicale founded in 2000. INSERM Transfert SA is headquartered in Paris, France. | Finance |
| Université de Paris 5 René Descartes | Consumer Services |
Kayentis SAS
Kayentis SAS Packaged SoftwareTechnology Services Kayentis SAS provides software in clinical trials solutions. It publishes and operates digital pen and smart paper solutions for the healthcare industry. The firm provides eCOA and eCRF solutions for trial management. It operates through its offices located in Gif-sur-Yvette and Saint Louis. The company was founded by Philippe Berna in 2009 and is headquartered in Gif-sur-Yvette, France. | Technology Services |
LBO France Gestion SAS
LBO France Gestion SAS Investment ManagersFinance LBO France Gestion SAS (LBO France) is one of the oldest independent private equity firms in France. Established in 1985, the firm manages leveraged buyout transactions through their small-cap, mid-cap and real estate funds. Headquartered in Paris, LBO France primarily targets French firms or companies which are based or which transact most of their business in France. | Finance |
